U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H21N
Molecular Weight 263.3774
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NORTRIPTYLINE

SMILES

CNCCC=C1c2ccccc2CCc3ccccc31

InChI

InChIKey=PHVGLTMQBUFIQQ-UHFFFAOYSA-N
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3

HIDE SMILES / InChI

Molecular Formula C19H21N
Molecular Weight 263.3774
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Nortriptyline is a second-generation tricyclic antidepressant (TCA) marketed as the hydrochloride salt under the trade names Sensoval, Aventyl, Pamelor, Norpress, Allegron, Noritren and Nortrilen. Nortriptyline is used in the treatment of depression and childhood nocturnal enuresis. Its off-label uses include treatment of postherpetic neuralgia, angioedema and smoking Cessation, and attention deficit hyperactivity disorder in some neurological disorders. It is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at beta-adrenergic receptors. Nortriptyline is US FDA-approved for the treatment of major depression. In the United Kingdom, it may also be used for treating nocturnal enuresis, with courses of treatment lasting no more than three months. The most common side effects include dry mouth, sedation, constipation, and increased appetite, mild blurred vision, tinnitus, occasionally hypomania or mania. An occasional side effect is a rapid or irregular heartbeat. Alcohol may exacerbate some of its side effects. However, fewer and milder side effects occur with nortriptyline than tertiary tricyclic antidepressants such as imipramine and amitriptyline. For this reason, nortriptyline is preferred to other tricyclic antidepressants, particularly with older adults, which also improves compliance.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
6.3 nM [Ki]
0.04 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
AVENTYL HYDROCHLORIDE

Approved Use

Nortriptyline hydrochloride capsules are indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states.

Launch Date

-1.62604794E11
Primary
AVENTYL HYDROCHLORIDE

Approved Use

Nortriptyline hydrochloride capsules are indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states.

Launch Date

-1.62604794E11
Primary
AVENTYL HYDROCHLORIDE

Approved Use

Nortriptyline hydrochloride capsules are indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states.

Launch Date

-1.62604794E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
36 nM
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORTRIPTYLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
16.91 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORTRIPTYLINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1591 nM × h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORTRIPTYLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
767.28 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORTRIPTYLINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
29.3 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORTRIPTYLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
32.75 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORTRIPTYLINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
8.35%
NORTRIPTYLINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Ki 450 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
likely (co-administration study)
Comment: Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug
minor
minor
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Amitriptyline and heart block.
1967 Jul 29
Correlation of subjective side effects with plasma concentrations of nortriptyline.
1970 Oct 3
Tricyclic antidepressants and monoamine oxidase inhibitors.
1971 Jun
Ophthalmological effects of nortriptyline--relationship to plasma level.
1972
Ototoxic reaction associated with use of nortriptyline hydrochloride: case report.
1972 Jun
Urinary retention in a neonate secondary to maternal ingestion of nortriptyline.
1972 Sep
Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.
1976 Feb
[Double blind clinical study of mianserin and nortriptyline (author's transl)].
1978 Sep-Oct
Hoarseness and aphonia as a side effect of tricyclic antidepressants.
1979 Dec
Cardiovascular side effects of long-term therapy with tricyclic antidepressants in the aged.
1979 May
Hoarseness and tricyclic antidepressants.
1980 May
Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference.
1981 Sep
Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline.
1983 May
Psychosis after discontinuation of nortriptyline.
1984 Apr
Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly.
1986 Oct
Occurrence of myoclonus in patients treated with cyclic antidepressants.
1987 Mar
Treatment-emergent depression with antidepressants in panic disorder.
1989 May-Jun
Myoclonus caused by a tricyclic antidepressant.
1990 Apr
Low dose tricyclic tachycardia.
1991 Jan
Tricyclics and heart failure.
1991 Nov
Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers.
1993
High initial nortriptyline doses in the treatment of depression.
1993 Feb
Midodrine for TCA-induced orthostatic hypotension.
1993 Nov
Sleep in bereavement-related depression during and after pharmacotherapy with nortriptyline.
1994 Apr-Jun
Recurrent hypotension immediately after seizures in nortriptyline overdose.
1994 Jul
The cardiovascular effects of bupropion and nortriptyline in depressed outpatients.
1994 Jun
Nortriptyline-induced fulminant hepatic failure.
1995 Jan
Mixed mania: apparent induction by a tricyclic antidepressant in five consecutively treated patients with bipolar depression.
1995 Jan 1
Depression following smoking cessation in women.
1996
Nortriptyline-induced hepatic failure.
1996 Feb
Determination of the dissociation constants (pKa) of secondary and tertiary amines in organic media by capillary electrophoresis and their role in the electrophoretic mobility order inversion.
2005 Mar 11
The adsorption mechanism of nortryptiline on C18-bonded Discovery.
2005 Nov 18
[A case of Brugada syndrome with convulsive seizure during antidepressant administration: relation of antidepressant agents and arrhythmia leading to sudden death].
2006
Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial.
2006 Aug
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
2006 Jun
Photoinduced chemiluminescence of pharmaceuticals.
2006 May 3
Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
2006 Oct 4
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
2007 Aug
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
Tobacco smoking cessation management: integrating varenicline in current practice.
2008
Nortriptyline protects mitochondria and reduces cerebral ischemia/hypoxia injury.
2008 Feb
Possession states precipitated by nortriptyline.
2008 May
Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s.
2008 May 9
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies.
2008 Nov 4
Trifluoperazine: a rynodine receptor agonist.
2009 Aug
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.
2009 Jun 15
A new strategy for antidepressant prescription.
2010
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease.
2012 Oct
Patents

Sample Use Guides

25mg PO q6-8hr. No more than 150 mg/day
Route of Administration: Oral
Two cell lines and eight primary cell cultures from metastatic melanoma deposits were exposed to three tricyclic drugs, amitriptyline, nortriptyline and clomipramine, at concentrations ranging from 200 to 6.25 µmol/l in the ATP-based tumour chemosensitivity assay. All three drugs showed activity, although nortriptyline was more active than clomipramine or amitriptyline in both cell lines and primary cell cultures, with an IC50 of 9, 27 and 33 µmol/l, respectively.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:56:48 UTC 2021
Edited
by admin
on Fri Jun 25 21:56:48 UTC 2021
Record UNII
BL03SY4LXB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NORTRIPTYLINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
NORAMITRIPTYLINE
Common Name English
NSC-757234
Code English
SESAVAL
Common Name English
NORTRIPTYLINE [VANDF]
Common Name English
3-(10,11-DIHYDRO-5H-DIBENZO(A,D)(7)ANNULEN-5-YLIDENE)-N-METHYLPROPAN-1-AMINE
Common Name English
1-PROPANAMINE, 3-(10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-N-METHYL-
Systematic Name English
LUMBECK
Common Name English
AVENTYL
Brand Name English
AMITRIPTYLINE HYDROCHLORIDE IMPURITY C [EP]
Common Name English
NORTRIPTYLINE [INN]
Common Name English
NORTRIPTYLINE [MI]
Common Name English
NORTRIPTYLINE [WHO-DD]
Common Name English
NCI-169453
Code English
NORTRILEN
Brand Name English
DESITRIPTILINA
Common Name English
10,11-DIHYDRO-N-METHYL-5H-DIBENZO(A,D)CYCLOHEPTENE-D(SUP5,.GAMMA.)-PROPYLAMINE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C94727
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
LIVERTOX 700
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
WHO-ATC N06AA10
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
NDF-RT N0000175752
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
WHO-VATC QN06AA10
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
Code System Code Type Description
LACTMED
Nortriptyline
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
INN
1328
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
FDA UNII
BL03SY4LXB
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
HSDB
3371
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
EPA CompTox
72-69-5
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
CAS
72-69-5
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
IUPHAR
2404
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-788-8
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
WIKIPEDIA
NORTRIPTYLINE
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
MERCK INDEX
M8074
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
1971
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
NCI_THESAURUS
C62060
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
ChEMBL
CHEMBL445
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
RXCUI
7531
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY RxNorm
MESH
D009661
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
EVMPD
SUB09380MIG
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
DRUG BANK
DB00540
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
PUBCHEM
4543
Created by admin on Fri Jun 25 21:56:48 UTC 2021 , Edited by admin on Fri Jun 25 21:56:48 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
Metabolizing reaction by CYP2D6: 2-Hydroxylation
TARGET -> INHIBITOR
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> INHIBITOR
IC50
BINDER->LIGAND
METABOLIC ENZYME -> SUBSTRATE
Pharmacological action: Tricyclic antidepressant drug (TCA)
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE ACTIVE
MAJOR
METABOLITE -> PARENT
MAJOR
PLASMA; URINE
METABOLITE -> PARENT
MINOR
PLASMA; URINE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC